Simulations Plus Inc

Simulations Plus Inc(SLP)のニュースとイベント

$18.500

0.000 (0.00%)終値時点

SLP のニュース

SLP のイベント

10/8 09:30

Simulations Plus Partners with Global Pharma to Develop AI Drug Models

Simulations Plus announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology, within an active therapeutic development program. The collaboration will evaluate how AI-enabled exploration of mechanistic model structures can substantially reduce the time required to build and evaluate QSP models. Under this collaboration, the pharmaceutical partner will use Turin within a hosted environment, supported by Simulations Plus scientists, who will provide scientific guidance throughout model evaluation.

10/6 09:30

Simulations Plus Completes Acquisition by Altaris, Shareholders Receive $18.50 per Share

Simulations Plus announced the completion of its acquisition by affiliates of Altaris. The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.

9/17 18:00

Simulations Plus Receives FDA License for ADMET Predictor

Simulations Plus announced that the FDA's Cosmetics Regulatory Science Branch has licensed ADMET Predictor to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology within the FDA. The ADMET Predictor platform provides researchers with advanced artificial intelligence and machine learning technology, descriptors, data, and predictive models to predict endpoint properties and systemic exposure in animals and humans.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める